Vertex Pharmaceuticals CEO Reshma Kewalramani's 2021 pay jumps 67% to $15M
Vertex Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 7, 2022
Vertex Pharmaceuticals reported fiscal year 2021 executive compensation information on April 7, 2022.
In 2021, five executives at Vertex Pharmaceuticals received on average a compensation package of $8.8M, a 10% decrease compared to previous year.
Average pay of disclosed executives at Vertex Pharmaceuticals
Reshma Kewalramani, Chief Executive Officer, received $15M in total, which increased by 67% compared to 2020. 72% of Kewalramani's compensation, or $11M, was in stock awards. Kewalramani also received $3M in non-equity incentive plan, $1.2M in salary, as well as $36K in other compensation.
Jeffrey M. Leiden, Chairman, received a compensation package of $8.2M, which decreased by 50% compared to previous year. 97% of the compensation package, or $7.9M, was in stock awards.
Stuart A. Arbuckle, Chief Operating Officer, earned $7.8M in 2021, a 7% increase compared to previous year.
Nia Tatsis, EVP & Chief Regulatory and Quality Officer, received $6.6M in 2021.
Charles F. Wagner, Jr, Chief Financial Officer, earned $6.2M in 2021, a 2% increase compared to previous year.
Related executives
Reshma Kewalramani
Vertex Pharmaceuticals
Chief Executive Officer
Charles Wagner
Vertex Pharmaceuticals
Chief Financial Officer
Stuart Arbuckle
Vertex Pharmaceuticals
Chief Operating Officer
Jeffrey Leiden
Vertex Pharmaceuticals
Chairman
Nia Tatsis
Vertex Pharmaceuticals
EVP & Chief Regulatory and Quality Officer
You may also like
Source: SEC filing on April 7, 2022.